<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="pmc-domain-id">440</journal-id><journal-id journal-id-type="pmc-domain">plosone</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS One</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>PLOS</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12431220</article-id><article-id pub-id-type="pmcid-ver">PMC12431220.1</article-id><article-id pub-id-type="pmcaid">12431220</article-id><article-id pub-id-type="pmcaiid">12431220</article-id><article-id pub-id-type="pmid">40938881</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0332490</article-id><article-id pub-id-type="publisher-id">PONE-D-25-10489</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Population Biology</subject><subj-group><subject>Population Metrics</subject><subj-group><subject>Death Rates</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Gastroenterology and Hepatology</subject><subj-group><subject>Liver Diseases</subject><subj-group><subject>Cirrhosis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Albumins</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Prognosis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Epidemiology</subject><subj-group><subject>Medical Risk Factors</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Physical Chemistry</subject><subj-group><subject>Ions</subject><subj-group><subject>Anions</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Clinical Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Hemorrhage</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Vascular Medicine</subject><subj-group><subject>Hemorrhage</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Clinical Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Sepsis</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Albumin-corrected anion gap as a predictive marker for mortality in critically Ill cirrhosis patients: an analysis based on the MIMIC-IV database</article-title><alt-title alt-title-type="running-head">Albumin-corrected anion gap predicts mortality in critically Ill cirrhosis patients</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="C">Ce</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="G">Guangdong</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="M">Min</given-names></name><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lv</surname><given-names initials="L">Lihong</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="M">Mengyuan</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7280-4820</contrib-id><name name-style="western"><surname>Yang</surname><given-names initials="X">Xingyi</given-names></name><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Gastroenterology Disease, Xian Ju People&#8217;s Hospital, Zhejiang Southeast Campus of Zhejiang Provincial People&#8217;s Hospital, Affiliated Xian Ju&#8217;s Hospital, Hangzhou Medical College. Xian Ju, Taizhou, Zhejiang, China</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Xi&#8217;an Jiao tong University, Xi&#8217;an, Shanxi, China</addr-line></aff><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Abdelaziz</surname><given-names initials="TS">Tarek Samy</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>Cairo University Kasr Alainy Faculty of Medicine, EGYPT</addr-line>
</aff><author-notes><corresp id="cor001">* E-mail: <email>375424576@qq.com</email></corresp><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn></author-notes><pub-date pub-type="epub"><day>12</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496058</issue-id><elocation-id>e0332490</elocation-id><history><date date-type="received"><day>28</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>1</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 11:25:14.803"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 Xu et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Xu et al</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pone.0332490.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="pone.0332490.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="editor-report" xml:lang="en" journal-id="PLoS One" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="40938881"><article-title>Albumin-corrected anion gap as a predictive marker for mortality in critically Ill cirrhosis patients: an analysis based on the MIMIC-IV database.</article-title><volume>20</volume><issue>9</issue><date><day>12</day><month>9</month><year>2025</year></date><fpage>e0332490</fpage><lpage>e0332490</lpage><source>PLoS One</source><pub-id pub-id-type="doi">10.1371/journal.pone.0332490</pub-id><pub-id pub-id-type="pmid">40938881</pub-id></related-article><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="reviewed-article" xml:lang="en" journal-id="PLoS One" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="40938881"><article-title>Albumin-corrected anion gap as a predictive marker for mortality in critically Ill cirrhosis patients: an analysis based on the MIMIC-IV database.</article-title><volume>20</volume><issue>9</issue><date><day>12</day><month>9</month><year>2025</year></date><fpage>e0332490</fpage><lpage>e0332490</lpage><source>PLoS One</source><pub-id pub-id-type="doi">10.1371/journal.pone.0332490</pub-id><pub-id pub-id-type="pmid">40938881</pub-id></related-article><abstract><sec id="sec001"><title>Background</title><p>The prognostic value of Albumin-Corrected Anion Gap (ACAG) has been extensively examined across a range of diseases; however, its relationship with short- and long-term survival in critically ill cirrhotic patients remains poorly understood. This study aims to investigate and elucidate the association between ACAG levels and mortality risk in this patient population.</p></sec><sec id="sec002"><title>Methods</title><p>Initial analysis involved a univariate assessment of 30-day mortality outcomes, followed by stratification of patient data using X-tile software. Multivariate modeling was employed to identify independent risk factors for mortality. Survival outcomes associated with ACAG levels were analyzed using Kaplan-Meier (K-M) survival curves, while diagnostic accuracy was evaluated through Receiver Operating Characteristic (ROC) curve analysis. Additionally, Restricted Cubic Spline (RCS) regression was utilized to investigate potential non-linear relationships between ACAG levels and mortality risk. Subgroup analyses further validated the interactions between ACAG levels and mortality outcomes in the context of liver cirrhosis.</p></sec><sec id="sec003"><title>Result</title><p>This study analyzed 2,826 participants, stratifying them into elevated (&gt;20) and normal (&#8804;20) ACAG groups based on X-tile-derived optimal cutoff. Elevated ACAG significantly correlated with higher mortality at 30, 90, 180, and 365 days (P&#8201;&lt;&#8201;0.05). Cox regression confirmed ACAG as an independent mortality predictor, supported by consistent hazard ratios (P&#8201;&lt;&#8201;0.05). K-M analysis revealed worse survival in the elevated ACAG group (P&#8201;&lt;&#8201;0.05). ROC curves indicated fair predictive value for cirrhosis mortality, while RCS analysis showed a linear ACAG mortality relationship. Subgroup analyses revealed no significant interaction effects between ACAG and demographic or clinical variables.</p></sec><sec id="sec004"><title>Conclusion</title><p>ACAG stands out as a reliable prognostic indicator, showing a meaningful link to mortality rates among critically ill patients with cirrhosis.</p></sec></abstract><funding-group><funding-statement>The author(s) received no specific funding for this work.</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="3"/><page-count count="16"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the manuscript and its <xref rid="sec019" ref-type="sec">Supporting Information</xref> files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the manuscript and its <xref rid="sec019" ref-type="sec">Supporting Information</xref> files.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>1. Introduction</title><p>Liver cirrhosis, a chronic and progressive liver disorder, is defined by hepatic fibrosis and structural abnormalities, leading to eventual liver dysfunction and failure [<xref rid="pone.0332490.ref001" ref-type="bibr">1</xref>]. Globally, its prevalence has risen steadily, particularly in developing regions where alcohol misuse and viral hepatitis infections are widespread [<xref rid="pone.0332490.ref002" ref-type="bibr">2</xref>]. Severe cirrhosis is frequently associated with life-threatening complications, including hepatic encephalopathy, ascites, gastrointestinal bleeding, and hepatorenal syndrome, all of which significantly elevate mortality risk [<xref rid="pone.0332490.ref003" ref-type="bibr">3</xref>]. Epidemiological studies report a five-year survival rate of approximately 50% for cirrhotic patients without liver transplantation, with critically ill individuals, particularly those presenting with multi-organ failure, experiencing even higher mortality rates [<xref rid="pone.0332490.ref004" ref-type="bibr">4</xref>]. End-stage liver disease not only profoundly diminishes patients&#8217; quality of life but also places a substantial economic strain on healthcare systems worldwide [<xref rid="pone.0332490.ref005" ref-type="bibr">5</xref>].</p><p>The anion gap (AG), calculated as the difference between unmeasured plasma anions and cations, is a pivotal diagnostic parameter for assessing acid-base homeostasis [<xref rid="pone.0332490.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0332490.ref007" ref-type="bibr">7</xref>]. While the reference range for AG typically falls between 8 and 16 mmol/L, cirrhotic patients frequently exhibit alterations in this value due to liver dysfunction-induced electrolyte imbalances and metabolic acidosis [<xref rid="pone.0332490.ref008" ref-type="bibr">8</xref>,<xref rid="pone.0332490.ref009" ref-type="bibr">9</xref>]. In critically ill cirrhotic patients, the complexity of acid-base disturbances is often heightened by liver failure and systemic complications such as infections, leading to more pronounced AG abnormalities [<xref rid="pone.0332490.ref010" ref-type="bibr">10</xref>]. Notably, hypoalbuminemia, a common feature in cirrhosis, may compromise the reliability of conventional AG measurements, necessitating adjustments for albumin levels [<xref rid="pone.0332490.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0332490.ref012" ref-type="bibr">12</xref>]. Consequently, the ACAG has emerged as a more precise diagnostic tool, offering enhanced insights into acid-base status and prognostic implications. ACAG has demonstrated significant prognostic value in various clinical conditions, including heart failure [<xref rid="pone.0332490.ref013" ref-type="bibr">13</xref>], acute myocardial infarction [<xref rid="pone.0332490.ref014" ref-type="bibr">14</xref>], and sepsis [<xref rid="pone.0332490.ref015" ref-type="bibr">15</xref>]. Despite these advancements, the association between ACAG and all-cause mortality in critically ill cirrhotic patients remains insufficiently investigated, warranting further research to elucidate its clinical significance in this population.</p><p>This study utilizes the MIMIC-IV database [<xref rid="pone.0332490.ref016" ref-type="bibr">16</xref>] to investigate the association between the ACAG and mortality in critically ill cirrhotic patients, aiming to establish a more reliable prognostic tool for clinical application. Through comprehensive correlation analysis, we seek to elucidate the clinical significance of ACAG in this population and contribute to improved patient management strategies.</p></sec><sec sec-type="materials|methods" id="sec006"><title>2. Materials and methods</title><sec id="sec007"><title>2.1. Database introduction</title><p>This study uses data from the MIMIC-IV database (v3.1), a public resource developed by MIT&#8217;s Laboratory of Computational Physiology. It includes detailed records of over 90,000 ICU patients at BIDMC (2012&#8211;2022), covering test results, prescriptions, vital signs, and hospitalization durations. The database has IRB approval from Beth Israel Deaconess Medical Center (2001P-001699/14). Patient confidentiality is maintained through de-identification (real data replaced with arbitrary numbers), eliminating the need for ethical approval and informed consent. The author accessed the database after completing the CITI Program (certificate #67058598). De-identified data can be found in the supplementary material &#8220;database&#8221;.</p></sec><sec id="sec008"><title>2.2. Inclusion and exclusion criteria</title><p>The diagnosis of cirrhosis was established based on the International Classification of Diseases (ICD) codes (ICD-9: 571.2, 571.5, 571.6; ICD-10: K70.30, K70.31, K74.3, K74.60, K74.69). Our study included 6597 patients with cirrhosis requiring ICU admission. We excluded patients with: (1) non-first ICU admissions; (2) ICU stays shorter than 24 hours; or (3) unavailable AG or albumin (ALB) data within 24 hours of admission. The final analysis included 2826 patients. <bold><xref rid="pone.0332490.g001" ref-type="fig">Fig 1</xref></bold> illustrates the study&#8217;s inclusion and exclusion process.</p><fig position="float" id="pone.0332490.g001" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0332490.g001</object-id><label>Fig 1</label><caption><title>A flow diagram of study participants.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0332490.g001.jpg"/></fig></sec><sec id="sec009"><title>2.3. Data collection and monitoring</title><p>We extracted data on demographic details, initial clinical vital signs, laboratory results, comorbidities, and treatment outcomes from the MIMIC-IV database, focusing on the first 24 hours of ICU admission. We meticulously tracked vital signs, including blood pressure and heart rate. Furthermore, an extensive array of laboratory indicators was documented, such as AG, albumin, total bilirubin, blood urea nitrogen (BUN), creatinine, blood glucose, white blood cell count (WBC), international normalized ratio (INR), transaminases, platelet count, sodium, potassium, and chloride levels. Data on complications closely associated with the prognosis of cirrhosis, which are of significant importance, were also collected. The complications associated with liver disease encompass ascites, variceal bleeding, hepatorenal syndrome (HRS), hepatic encephalopathy (HE), and spontaneous bacterial peritonitis (SBP). Additionally, we included established clinical scoring systems, namely the MELD [<xref rid="pone.0332490.ref017" ref-type="bibr">17</xref>] (Model for End-Stage Liver Disease) score as well as the SOFA [<xref rid="pone.0332490.ref018" ref-type="bibr">18</xref>] (Sequential Organ Failure Assessment) score, both of which are extensively utilized to evaluate disease severity and predict clinical outcomes. The ACAG served as the core variable in this study. The calculation formula for the ACAG (mmol/l) is: ACAG (mmol/l) = AG (mmol/l) + {4.4 &#8211; ALB (g/dl)} &#215; 2.5. The model&#8217;s continuous variable data were constructed using the average values of parameters recorded within the first 24 hours of ICU admission. Patients were followed up for a minimum of 365 days to evaluate both short-term and long-term prognostic outcomes. The primary endpoint of this study was all-cause mortality at 30-day, 90-day, 180-day, and 365-day intervals after admission.</p></sec><sec id="sec010"><title>2.4. Statistical analyses</title><p>The normality of continuous variables was evaluated using Shapiro-Wilk tests. Normally distributed data were presented as mean&#8201;&#177;&#8201;standard deviation (SD) and analyzed with independent samples t-tests, while non-normally distributed variables were expressed as median (interquartile range, IQR) and analyzed using Mann-Whitney U tests. Data with &gt;20% missing values were excluded; those with &#8804;20% underwent random forest imputation. Random forest imputation is a powerful tool for data completion. Its non-parametric nature enables it to model complex nonlinear relationships in data without strict normality assumptions [<xref rid="pone.0332490.ref019" ref-type="bibr">19</xref>]. Also, compared to regression-based methods, it shows strong robustness to outliers, improving the accuracy of missing value estimation [<xref rid="pone.0332490.ref020" ref-type="bibr">20</xref>].</p><p>The cutoff value of ACAG was determined to be 20 mmol/L by optimizing 30-day post-admission mortality using X-tile analysis (v3.6.1, Yale University, USA) as well as referring to prior studies [<xref rid="pone.0332490.ref021" ref-type="bibr">21</xref>&#8211;<xref rid="pone.0332490.ref023" ref-type="bibr">23</xref>], with patients being divided into two groups: those with ACAG &#8804;20 mmol/L and those with ACAG &gt;20 mmol/L. The Cox model was used for univariate and multivariate analyses to identify independent prognostic factors for 30-day mortality in cirrhosis patients. Results were reported as Hazard ratios (HRs) with 95% confidence intervals (CIs). KM curves were plotted, and the log-rank test compared the groups. ROC analysis evaluated the predictive accuracy of ACAG, AG, ALB, SOFA score, and MELD score for mortality. Sensitivity, specificity, and AUC were calculated. Restrictive cubic spline (RCS) analysis explored the relationship between ACAG and cirrhosis prognosis. Subgroup analyses assessed the impact of factors like age, sex, race, sepsis, AKI (Acute Kidney Injury), variceal bleeding, SBP, hepatic encephalopathy, HRS, and CRRT (Continuous Renal Replacement Therapy) treatment on ACAG. To account for multiple testing, significance thresholds were adjusted via Bonferroni correction: P&#8201;&lt;&#8201;0.004(0.05/12) for Cox regressions and P&#8201;&lt;&#8201;0.005 (0.05/9) for subgroup analyses. All statistical analyses were performed using R software (version 4.2.2, R Foundation for Statistical Computing, Vienna, Austria) and MSTATA software (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mstata.com/" ext-link-type="uri">https://www.mstata.com/</ext-link>). The code used is available in the supplementary material &#8220;R.zip&#8221;.</p></sec></sec><sec sec-type="results" id="sec011"><title>3. Results</title><sec id="sec012"><title>3.1. Characteristics of patients at baseline</title><p>The study encompassed a total of 2,876 patients. The mean age of the patients was 59 years, with 64.0% males and 65.5% whites. When compared to the survivor group, the mortality group exhibited higher values in age, heart rate, respiratory rate, RDW, white blood cell count, AG, total calcium, ACAG, INR, sodium ions, BUN, total bilirubin, and creatinine. Moreover, their MELD and SOFA scores were also elevated (28.0 vs. 18.0, 10.0 vs. 8.0). In terms of complications and treatments, the mortality group had a higher proportion of patients with sepsis (46.4% vs. 20.9%), AKI (73.0% vs. 54.6%), SBP (14.3% vs. 9.2%), ascites (59.2% vs. 47.1%), HRS (26.1% vs. 12.0%), HE (12.3% vs. 9.5%), CRRT (25.7% vs. 11.3%), and the use of ventilators (84.6% vs. 78.1%). However, no statistically significant differences were found between the two groups regarding gender, diabetes, and variceal bleeding (P&#8201;&#8805;&#8201;0.05). The baseline characteristics of patients in both groups are presented in <bold><xref rid="pone.0332490.t001" ref-type="table">Table 1</xref></bold>.</p><table-wrap position="float" id="pone.0332490.t001" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0332490.t001</object-id><label>Table 1</label><caption><title>Patient demographics and baseline characteristics.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0332490.t001g" position="float" orientation="portrait" xlink:href="pone.0332490.t001.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="left" rowspan="1" colspan="1">All patients(n&#8201;=&#8201;2826)</th><th align="left" rowspan="1" colspan="1">Survivors (n&#8201;=&#8201;1956)</th><th align="left" rowspan="1" colspan="1">Nonsurvivors (n&#8201;=&#8201;870)</th><th align="left" rowspan="1" colspan="1">p-value</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">
<bold>Demographic</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Age(year)</td><td align="left" rowspan="1" colspan="1">59 (52, 67)</td><td align="left" rowspan="1" colspan="1">59 (51, 66)</td><td align="left" rowspan="1" colspan="1">61 (53, 68)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender, n (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.386</td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">1810 (64.0%)</td><td align="left" rowspan="1" colspan="1">1263 (64.6%)</td><td align="left" rowspan="1" colspan="1">547 (62.9%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">1016 (36.0%)</td><td align="left" rowspan="1" colspan="1">693 (35.4%)</td><td align="left" rowspan="1" colspan="1">323 (37.1%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Race, n (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" rowspan="1" colspan="1">White</td><td align="left" rowspan="1" colspan="1">1,852 (65.5%)</td><td align="left" rowspan="1" colspan="1">1312 (67.1%)</td><td align="left" rowspan="1" colspan="1">540 (62.1%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">735 (26.0%)</td><td align="left" rowspan="1" colspan="1">475 (24.3%)</td><td align="left" rowspan="1" colspan="1">260 (29.9%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Black</td><td align="left" rowspan="1" colspan="1">239 (8.5%)</td><td align="left" rowspan="1" colspan="1">169 (8.6%)</td><td align="left" rowspan="1" colspan="1">70 (8.0%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="5" rowspan="1">
<bold>Vital Signs</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart rate (beats/min)</td><td align="left" rowspan="1" colspan="1">88 (77, 100)</td><td align="left" rowspan="1" colspan="1">87 (76, 98)</td><td align="left" rowspan="1" colspan="1">91 (79, 103)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td><td align="left" rowspan="1" colspan="1">111 (101, 118)</td><td align="left" rowspan="1" colspan="1">113 (102, 121)</td><td align="left" rowspan="1" colspan="1">108 (98, 116)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic Blood Pressure (mmHg)</td><td align="left" rowspan="1" colspan="1">63 (56, 68)</td><td align="left" rowspan="1" colspan="1">63 (57, 69)</td><td align="left" rowspan="1" colspan="1">60 (53, 65)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Respiratory rate (beats/min)</td><td align="left" rowspan="1" colspan="1">18.0 (16.0, 21.0)</td><td align="left" rowspan="1" colspan="1">18.0 (16.0, 20.3)</td><td align="left" rowspan="1" colspan="1">19.0 (17.0, 23.0)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Temperature (&#176;C)</td><td align="left" rowspan="1" colspan="1">36.78 (36.59, 37.04)</td><td align="left" rowspan="1" colspan="1">36.82(36.64,37.07)</td><td align="left" rowspan="1" colspan="1">36.72 (36.49, 36.91)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">
<bold>Laboratory Indicators</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">hemoglobin(g/dl)</td><td align="left" rowspan="1" colspan="1">9.16(8.03, 10.51)</td><td align="left" rowspan="1" colspan="1">9.30 (8.15, 10.63)</td><td align="left" rowspan="1" colspan="1">8.94 (7.83, 10.25)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">platelet(10^9/L)</td><td align="left" rowspan="1" colspan="1">93 (62, 145)</td><td align="left" rowspan="1" colspan="1">94 (64, 145)</td><td align="left" rowspan="1" colspan="1">89 (58, 144)</td><td align="left" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" rowspan="1" colspan="1">RDW (%)</td><td align="left" rowspan="1" colspan="1">17.08 (15.49, 19.15)</td><td align="left" rowspan="1" colspan="1">16.77(15.30,18.78)</td><td align="left" rowspan="1" colspan="1">17.85 (16.00, 20.05)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">RBC (10^9/L)</td><td align="left" rowspan="1" colspan="1">2.95 (2.55, 3.39)</td><td align="left" rowspan="1" colspan="1">3.01 (2.61, 3.43)</td><td align="left" rowspan="1" colspan="1">2.82 (2.46, 3.27)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">WBC (10^9/L)</td><td align="left" rowspan="1" colspan="1">10 (6, 14)</td><td align="left" rowspan="1" colspan="1">9 (6, 13)</td><td align="left" rowspan="1" colspan="1">11 (7, 17)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Albumin(mg/dl)</td><td align="left" rowspan="1" colspan="1">2.95 (2.53, 3.40)</td><td align="left" rowspan="1" colspan="1">3.00 (2.60, 3.40)</td><td align="left" rowspan="1" colspan="1">2.90 (2.45, 3.40)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Anion gap (m Eq/l)</td><td align="left" rowspan="1" colspan="1">14.7 (12.0, 18.0)</td><td align="left" rowspan="1" colspan="1">14.0 (11.7, 16.8)</td><td align="left" rowspan="1" colspan="1">16.5 (13.0, 20.0)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">TCa (mg/dl)</td><td align="left" rowspan="1" colspan="1">8.30 (7.80, 8.85)</td><td align="left" rowspan="1" colspan="1">8.27 (7.80, 8.80)</td><td align="left" rowspan="1" colspan="1">8.33 (7.80, 8.95)</td><td align="left" rowspan="1" colspan="1">0.032</td></tr><tr><td align="left" rowspan="1" colspan="1">glucose (mg/dl)</td><td align="left" rowspan="1" colspan="1">131 (106, 172)</td><td align="left" rowspan="1" colspan="1">133 (108, 181)</td><td align="left" rowspan="1" colspan="1">125 (100, 157)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Potassium (m Eq/l)</td><td align="left" rowspan="1" colspan="1">4.15 (3.80, 4.63)</td><td align="left" rowspan="1" colspan="1">4.12 (3.80, 4.55)</td><td align="left" rowspan="1" colspan="1">4.23 (3.80, 4.80)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Sodium (m Eq/l)</td><td align="left" rowspan="1" colspan="1">137 (133, 141)</td><td align="left" rowspan="1" colspan="1">137 (134, 141)</td><td align="left" rowspan="1" colspan="1">137 (132, 140)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">INR</td><td align="left" rowspan="1" colspan="1">1.70 (1.43, 2.15)</td><td align="left" rowspan="1" colspan="1">1.63 (1.40, 2.00)</td><td align="left" rowspan="1" colspan="1">2.00 (1.60, 2.50)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">ALT(IU/L)</td><td align="left" rowspan="1" colspan="1">35 (20, 90)</td><td align="left" rowspan="1" colspan="1">35 (20, 104)</td><td align="left" rowspan="1" colspan="1">36 (21, 74)</td><td align="left" rowspan="1" colspan="1">0.413</td></tr><tr><td align="left" rowspan="1" colspan="1">AST(IU/L)</td><td align="left" rowspan="1" colspan="1">74 (41, 191)</td><td align="left" rowspan="1" colspan="1">70 (40, 198)</td><td align="left" rowspan="1" colspan="1">79 (42, 175)</td><td align="left" rowspan="1" colspan="1">0.321</td></tr><tr><td align="left" rowspan="1" colspan="1">Total bilirubin(mg/dl)</td><td align="left" rowspan="1" colspan="1">3 (1, 7)</td><td align="left" rowspan="1" colspan="1">3 (1, 6)</td><td align="left" rowspan="1" colspan="1">4 (2, 12)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">creatinine(mg/dl)</td><td align="left" rowspan="1" colspan="1">1.30 (0.85, 2.25)</td><td align="left" rowspan="1" colspan="1">1.17 (0.80, 1.90)</td><td align="left" rowspan="1" colspan="1">1.80 (1.06, 3.10)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">BUN mg/dl)</td><td align="left" rowspan="1" colspan="1">28 (17, 47)</td><td align="left" rowspan="1" colspan="1">25 (16, 42)</td><td align="left" rowspan="1" colspan="1">36 (21, 60)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">SOFA</td><td align="left" rowspan="1" colspan="1">8.0 (6.0, 11.0)</td><td align="left" rowspan="1" colspan="1">8.0 (5.0, 10.0)</td><td align="left" rowspan="1" colspan="1">10.0 (8.0, 14.0)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">MELD</td><td align="left" rowspan="1" colspan="1">21 (13, 28)</td><td align="left" rowspan="1" colspan="1">18 (12, 25)</td><td align="left" rowspan="1" colspan="1">26 (18, 33)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">ACAG (m Eq/l)</td><td align="left" rowspan="1" colspan="1">18.0 (15.8, 21.3)</td><td align="left" rowspan="1" colspan="1">17.5 (15.3, 20.0)</td><td align="left" rowspan="1" colspan="1">20.3 (17.1, 23.5)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">
<bold>Comorbidities</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Sepsis, (n %)</td><td align="left" rowspan="1" colspan="1">813 (28.8%)</td><td align="left" rowspan="1" colspan="1">409 (20.9%)</td><td align="left" rowspan="1" colspan="1">404 (46.4%)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">AKI, n (%)</td><td align="left" rowspan="1" colspan="1">1,703 (60.3%)</td><td align="left" rowspan="1" colspan="1">1,068 (54.6%)</td><td align="left" rowspan="1" colspan="1">635 (73.0%)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Variceal Bleeding, n (%)</td><td align="left" rowspan="1" colspan="1">168 (5.9%)</td><td align="left" rowspan="1" colspan="1">118 (6.0%)</td><td align="left" rowspan="1" colspan="1">50 (5.7%)</td><td align="left" rowspan="1" colspan="1">0.767</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP, n (%)</td><td align="left" rowspan="1" colspan="1">304 (10.8%)</td><td align="left" rowspan="1" colspan="1">180 (9.2%)</td><td align="left" rowspan="1" colspan="1">124 (14.3%)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Ascites, n (%)</td><td align="left" rowspan="1" colspan="1">1,437 (50.8%)</td><td align="left" rowspan="1" colspan="1">922 (47.1%)</td><td align="left" rowspan="1" colspan="1">515 (59.2%)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">HRS, n (%)</td><td align="left" rowspan="1" colspan="1">457 (16.2%)</td><td align="left" rowspan="1" colspan="1">45 (12.0%)</td><td align="left" rowspan="1" colspan="1">35 (26.1%)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">HE, n (%)</td><td align="left" rowspan="1" colspan="1">293 (10.4%)</td><td align="left" rowspan="1" colspan="1">186 (9.5%)</td><td align="left" rowspan="1" colspan="1">107 (12.3%)</td><td align="left" rowspan="1" colspan="1">0.025</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes, n (%)</td><td align="left" rowspan="1" colspan="1">824 (29.2%)</td><td align="left" rowspan="1" colspan="1">561 (28.7%)</td><td align="left" rowspan="1" colspan="1">263 (30.2%)</td><td align="left" rowspan="1" colspan="1">0.403</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart Failure, n (%)</td><td align="left" rowspan="1" colspan="1">500 (17.7%)</td><td align="left" rowspan="1" colspan="1">325 (16.6%)</td><td align="left" rowspan="1" colspan="1">175 (20.1%)</td><td align="left" rowspan="1" colspan="1">0.024</td></tr><tr><td align="left" colspan="5" rowspan="1">
<bold>Treatment</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Ventilator, n (%)</td><td align="left" rowspan="1" colspan="1">2,263 (80.1%)</td><td align="left" rowspan="1" colspan="1">1,527 (78.1%)</td><td align="left" rowspan="1" colspan="1">736 (84.6%)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">CRRT, n (%)</td><td align="left" rowspan="1" colspan="1">445 (15.7%)</td><td align="left" rowspan="1" colspan="1">221 (11.3%)</td><td align="left" rowspan="1" colspan="1">224 (25.7%)</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>T Ca: Total calcium; BUN: Blood Urea Nitrogen; AST: aspartate aminotransferase; ALT: alanine aminotransferase; RDW: Red Cell Distribution Width; RBC: Red Blood Cell; WBC: white blood cell; INR: international normalized ratio; MELD: Model for End-Stage Liver Disease; CRRT: continuous renal replacement therapy; AKI: acute kidney injury; ACAG: Albumin Corrected Anion Gap; HE: Hepatic Encephalopathy; SOFA, Sepsis-related Organ Failure Assessment score. SBP: Spontaneous bacterial peritonitis.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec013"><title>3.2. Cox regression analysis of ACAG and mortality in cirrhosis patients</title><p>The Cox proportional hazards model demonstrated a consistent association between elevated ACAG and increased mortality risk across all assessed time periods. Specifically, compared to the normal group, elevated ACAG was linked to higher mortality rates at 30 days (HR&#8201;=&#8201;2.62, 95% CI: 2.30&#8211;3.00, P&#8201;&lt;&#8201;0.001), 90 days (HR&#8201;=&#8201;2.48, 95% CI: 2.18&#8211;2.81, P&#8201;&lt;&#8201;0.001), 180 days (HR&#8201;=&#8201;2.49, 95% CI: 2.19&#8211;2.82, P&#8201;&lt;&#8201;0.001), and 365 days (HR&#8201;=&#8201;2.50, 95% CI: 2.21&#8211;2.83, P&#8201;&lt;&#8201;0.001).</p><p>In multivariable analysis, Model 1 adjusted for age and gender, and the elevated ACAG group still exhibited significantly elevated mortality risks at each time point: 30 days (HR&#8201;=&#8201;2.63, 95% CI: 2.30&#8211;3.01, P&#8201;&lt;&#8201;0.001), 90 days (HR&#8201;=&#8201;2.48, 95% CI: 2.19&#8211;2.82, P&#8201;&lt;&#8201;0.001), 180 days (HR&#8201;=&#8201;2.49, 95% CI: 2.20&#8211;2.83, P&#8201;&lt;&#8201;0.001), and 365 days (HR&#8201;=&#8201;2.51, 95% CI: 2.21&#8211;2.84, P&#8201;&lt;&#8201;0.001).</p><p>Moreover, Model 2, which accounted for additional covariates, confirmed the independent prognostic value of ACAG. The hazard ratios for the elevated ACAG group were 1.77 (95% CI: 1.52&#8211;2.06, P&#8201;&lt;&#8201;0.001) at 30 days, 1.64 (95% CI: 1.42&#8211;1.89, P&#8201;&lt;&#8201;0.001) at 90 days, 1.65 (95% CI: 1.43&#8211;1.90, P&#8201;&lt;&#8201;0.001) at 180 days, and 1.67 (95% CI: 1.45&#8211;1.92, P&#8201;&lt;&#8201;0.001) at 365 days.</p><p>These findings underscore the robust relationship between elevated ACAG levels and mortality risk in cirrhosis patients across different follow-up intervals, highlighting its potential as a significant prognostic indicator. For more details, refer to <bold><xref rid="pone.0332490.t002" ref-type="table">Table 2</xref></bold>.</p><table-wrap position="float" id="pone.0332490.t002" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0332490.t002</object-id><label>Table 2</label><caption><title>Association between ACAG and mortality in patients with cirrhosis.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0332490.t002g" position="float" orientation="portrait" xlink:href="pone.0332490.t002.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Outcome</th><th align="left" rowspan="1" colspan="1">Unadjusted HR (95%CI)</th><th align="left" rowspan="1" colspan="1">Model1 HR (95%CI)</th><th align="left" rowspan="1" colspan="1">Model2 HR (95%CI)</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">
<bold>30-d</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">ACAG&#8804;20</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">ACAG&gt;20</td><td align="left" rowspan="1" colspan="1">2.62(2.30, 3.00)</td><td align="left" rowspan="1" colspan="1">2.63(2.30, 3.01)</td><td align="left" rowspan="1" colspan="1">1.77(1.52, 2.06)</td></tr><tr><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="4" rowspan="1">
<bold>90-d</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">ACAG&#8804;20</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">ACAG&gt;20</td><td align="left" rowspan="1" colspan="1">2.48(2.18, 2.81)</td><td align="left" rowspan="1" colspan="1">2.48(2.19, 2.82)</td><td align="left" rowspan="1" colspan="1">1.64(1.42, 1.89)</td></tr><tr><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="4" rowspan="1">
<bold>180-d</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">ACAG&#8804;20</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">ACAG&gt;20</td><td align="left" rowspan="1" colspan="1">2.49(2.19, 2.82)</td><td align="left" rowspan="1" colspan="1">2.49(2.20, 2.83)</td><td align="left" rowspan="1" colspan="1">1.65(1.43, 1.90)</td></tr><tr><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="4" rowspan="1">
<bold>365-d</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">ACAG&#8804;20</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">ACAG&gt;20</td><td align="left" rowspan="1" colspan="1">2.50(2.21, 2.83)</td><td align="left" rowspan="1" colspan="1">2.51(2.21, 2.84)</td><td align="left" rowspan="1" colspan="1">1.67(1.45, 1.92)</td></tr><tr><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>Model 1: Adjusted age and Gender.</p></fn><fn id="t002fn002"><p>Model 2: Model 1&#8201;+&#8201;Temperature, Platelet, WBC, Sodium, INR, BUN, Sepsis, Variceal bleeding, SBP, Ascites, HRS, HE, AKI, and CRRT.</p></fn></table-wrap-foot></table-wrap><p>To bolster confidence in our findings, we performed a sensitivity analysis using the optimal cutoff value from the 30-day mortality ROC curve. Specifically, we analyzed ACAG at a cutoff value of 18.375. After adjusting for all potential confounding covariates, all P-values across the assessed time points were P&#8201;&lt;&#8201;0.001, underscoring the stability and significance of our results. For further details, see <xref rid="pone.0332490.s001" ref-type="supplementary-material">S1 Table</xref>.</p></sec><sec id="sec014"><title>3.3. Analysis of Kaplan-Meier and ROC Curves</title><p>The K-M survival analysis revealed significant differences in mortality rates between patients with elevated ACAG levels and those with normal levels at 30 days (47.5% vs. 28.9%, P&#8201;&lt;&#8201;0.001), 90 days (51.0% vs. 26.0%, P&#8201;&lt;&#8201;0.001), 180 days (51.6% vs. 26.2%, P&#8201;&lt;&#8201;0.001), and 365 days (52.3% vs. 26.6%, P&#8201;&lt;&#8201;0.001). These results are shown in <bold><xref rid="pone.0332490.g002" ref-type="fig">Fig 2</xref></bold>.</p><fig position="float" id="pone.0332490.g002" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0332490.g002</object-id><label>Fig 2</label><caption><title>K-M survival analysis curves for all-cause mortality in patients with cirrhosis at 30-d (A), 90-d (B),180-d (C) and 365-d (D) of hospital admission.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0332490.g002.jpg"/></fig><p>Compared to AG or albumin alone, the ACAG demonstrated better predictive value for both short- and long-term mortality.</p><p>For 30-day, 90-day, 180-day, and 365-day mortality predictions, ACAG achieved AUCs of 0.671 (CI: 0.649&#8211;0.693), 0.663 (CI: 0.641&#8211;0.684), 0.664 (CI: 0.643&#8211;0.685), and 0.665 (CI: 0.643&#8211;0.686), respectively, consistently outperforming AG (0.651, 0.647, 0.649, 0.649) and albumin (0.541, 0.534, 0.534, 0.534).</p><p>The predictive performance was further enhanced when ACAG was combined with SOFA or MELD scores. The SOFA+ACAG model achieved AUCs of 0.704, 0.699, 0.701, and 0.700 for 30-day, 90-day, 180-day, and 365-day mortality, respectively. Similarly, the MELD+ACAG combination demonstrated robust performance, with AUCs of 0.710, 0.709, 0.711, and 0.711, respectively. More details are provided in <bold><xref rid="pone.0332490.t003" ref-type="table">Table 3</xref></bold> and <bold><xref rid="pone.0332490.g003" ref-type="fig">Fig 3</xref></bold>.</p><table-wrap position="float" id="pone.0332490.t003" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0332490.t003</object-id><label>Table 3</label><caption><title>Information of ROC curves in <xref rid="pone.0332490.g003" ref-type="fig">Fig 3</xref>.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0332490.t003g" position="float" orientation="portrait" xlink:href="pone.0332490.t003.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">AUC (%)</th><th align="left" rowspan="1" colspan="1">95%CI (%)</th><th align="left" rowspan="1" colspan="1">Threshold</th><th align="left" rowspan="1" colspan="1">Sensitivity</th><th align="left" rowspan="1" colspan="1">Specificity</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1">
<bold>30-d</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>ACAG</bold>
</td><td align="left" rowspan="1" colspan="1">0.671</td><td align="left" rowspan="1" colspan="1">0.649 - 0.693</td><td align="left" rowspan="1" colspan="1">18.375</td><td align="left" rowspan="1" colspan="1">0.571</td><td align="left" rowspan="1" colspan="1">0.700</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>AG</bold>
</td><td align="left" rowspan="1" colspan="1">0.651</td><td align="left" rowspan="1" colspan="1">0.628 - 0.673</td><td align="left" rowspan="1" colspan="1">17.200</td><td align="left" rowspan="1" colspan="1">0.461</td><td align="left" rowspan="1" colspan="1">0.783</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Albumin</bold>
</td><td align="left" rowspan="1" colspan="1">0.541</td><td align="left" rowspan="1" colspan="1">0.517 - 0.564</td><td align="left" rowspan="1" colspan="1">2.600</td><td align="left" rowspan="1" colspan="1">0.368</td><td align="left" rowspan="1" colspan="1">0.724</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>SOFA</bold>
</td><td align="left" rowspan="1" colspan="1">0.680</td><td align="left" rowspan="1" colspan="1">0.658 - 0.702</td><td align="left" rowspan="1" colspan="1">9.000</td><td align="left" rowspan="1" colspan="1">0.670</td><td align="left" rowspan="1" colspan="1">0.581</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MELD</bold>
</td><td align="left" rowspan="1" colspan="1">0.692</td><td align="left" rowspan="1" colspan="1">0.671 - 0.713</td><td align="left" rowspan="1" colspan="1">24.000</td><td align="left" rowspan="1" colspan="1">0.585</td><td align="left" rowspan="1" colspan="1">0.585</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>SOFA+ACAG</bold>
</td><td align="left" rowspan="1" colspan="1">0.704</td><td align="left" rowspan="1" colspan="1">0.683 - 0.725</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.278</td><td align="left" rowspan="1" colspan="1">0.928</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MELD+ACAG</bold>
</td><td align="left" rowspan="1" colspan="1">0.710</td><td align="left" rowspan="1" colspan="1">0.690 - 0.731</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.271</td><td align="left" rowspan="1" colspan="1">0.923</td></tr><tr><td align="left" colspan="6" rowspan="1">
<bold>90-d</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>ACAG</bold>
</td><td align="left" rowspan="1" colspan="1">0.663</td><td align="left" rowspan="1" colspan="1">0.641 - 0.684</td><td align="left" rowspan="1" colspan="1">18.375</td><td align="left" rowspan="1" colspan="1">0.551</td><td align="left" rowspan="1" colspan="1">0.705</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>AG</bold>
</td><td align="left" rowspan="1" colspan="1">0.647</td><td align="left" rowspan="1" colspan="1">0.625 - 0.669</td><td align="left" rowspan="1" colspan="1">15.500</td><td align="left" rowspan="1" colspan="1">0.595</td><td align="left" rowspan="1" colspan="1">0.645</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Albumin</bold>
</td><td align="left" rowspan="1" colspan="1">0.534</td><td align="left" rowspan="1" colspan="1">0.511 - 0.557</td><td align="left" rowspan="1" colspan="1">2.600</td><td align="left" rowspan="1" colspan="1">0.362</td><td align="left" rowspan="1" colspan="1">0.726</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>SOFA</bold>
</td><td align="left" rowspan="1" colspan="1">0.676</td><td align="left" rowspan="1" colspan="1">0.655 - 0.697</td><td align="left" rowspan="1" colspan="1">9.000</td><td align="left" rowspan="1" colspan="1">0.661</td><td align="left" rowspan="1" colspan="1">0.591</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MELD</bold>
</td><td align="left" rowspan="1" colspan="1">0.695</td><td align="left" rowspan="1" colspan="1">0.675 - 0.716</td><td align="left" rowspan="1" colspan="1">24.000</td><td align="left" rowspan="1" colspan="1">0.561</td><td align="left" rowspan="1" colspan="1">0.545</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>SOFA+ACAG</bold>
</td><td align="left" rowspan="1" colspan="1">0.699</td><td align="left" rowspan="1" colspan="1">0.679 - 0.720</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.323</td><td align="left" rowspan="1" colspan="1">0.904</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MELD+ACAG</bold>
</td><td align="left" rowspan="1" colspan="1">0.709</td><td align="left" rowspan="1" colspan="1">0.689 - 0.730</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.328</td><td align="left" rowspan="1" colspan="1">0.903</td></tr><tr><td align="left" colspan="6" rowspan="1">
<bold>180-d</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>ACAG</bold>
</td><td align="left" rowspan="1" colspan="1">0.664</td><td align="left" rowspan="1" colspan="1">0.643 - 0.685</td><td align="left" rowspan="1" colspan="1">18.375</td><td align="left" rowspan="1" colspan="1">0.552</td><td align="left" rowspan="1" colspan="1">0.706</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>AG</bold>
</td><td align="left" rowspan="1" colspan="1">0.649</td><td align="left" rowspan="1" colspan="1">0.627 - 0.670</td><td align="left" rowspan="1" colspan="1">15.500</td><td align="left" rowspan="1" colspan="1">0.596</td><td align="left" rowspan="1" colspan="1">0.646</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Albumin</bold>
</td><td align="left" rowspan="1" colspan="1">0.534</td><td align="left" rowspan="1" colspan="1">0.511 - 0.557</td><td align="left" rowspan="1" colspan="1">2.600</td><td align="left" rowspan="1" colspan="1">0.361</td><td align="left" rowspan="1" colspan="1">0.726</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>SOFA</bold>
</td><td align="left" rowspan="1" colspan="1">0.677</td><td align="left" rowspan="1" colspan="1">0.656 - 0.698</td><td align="left" rowspan="1" colspan="1">9.000</td><td align="left" rowspan="1" colspan="1">0.661</td><td align="left" rowspan="1" colspan="1">0.592</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MELD</bold>
</td><td align="left" rowspan="1" colspan="1">0.696</td><td align="left" rowspan="1" colspan="1">0.676 - 0.717</td><td align="left" rowspan="1" colspan="1">24.000</td><td align="left" rowspan="1" colspan="1">0.562</td><td align="left" rowspan="1" colspan="1">0.750</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>SOFA+ACAG</bold>
</td><td align="left" rowspan="1" colspan="1">0.701</td><td align="left" rowspan="1" colspan="1">0.680 - 0.721</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.329</td><td align="left" rowspan="1" colspan="1">0.904</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MELD+ACAG</bold>
</td><td align="left" rowspan="1" colspan="1">0.711</td><td align="left" rowspan="1" colspan="1">0.691 - 0.731</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.331</td><td align="left" rowspan="1" colspan="1">0.900</td></tr><tr><td align="left" colspan="6" rowspan="1">
<bold>365-d</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>ACAG</bold>
</td><td align="left" rowspan="1" colspan="1">0.665</td><td align="left" rowspan="1" colspan="1">0.643 - 0.686</td><td align="left" rowspan="1" colspan="1">19.455</td><td align="left" rowspan="1" colspan="1">0.470</td><td align="left" rowspan="1" colspan="1">0.789</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>AG</bold>
</td><td align="left" rowspan="1" colspan="1">0.649</td><td align="left" rowspan="1" colspan="1">0.627 - 0.671</td><td align="left" rowspan="1" colspan="1">15.670</td><td align="left" rowspan="1" colspan="1">0.573</td><td align="left" rowspan="1" colspan="1">0.672</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Albumin</bold>
</td><td align="left" rowspan="1" colspan="1">0.534</td><td align="left" rowspan="1" colspan="1">0.511 - 0.557</td><td align="left" rowspan="1" colspan="1">2.600</td><td align="left" rowspan="1" colspan="1">0.360</td><td align="left" rowspan="1" colspan="1">0.726</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>SOFA</bold>
</td><td align="left" rowspan="1" colspan="1">0.676</td><td align="left" rowspan="1" colspan="1">0.655 - 0.697</td><td align="left" rowspan="1" colspan="1">9.000</td><td align="left" rowspan="1" colspan="1">0.660</td><td align="left" rowspan="1" colspan="1">0.592</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MELD</bold>
</td><td align="left" rowspan="1" colspan="1">0.696</td><td align="left" rowspan="1" colspan="1">0.675 - 0.716</td><td align="left" rowspan="1" colspan="1">24.000</td><td align="left" rowspan="1" colspan="1">0.559</td><td align="left" rowspan="1" colspan="1">0.750</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>SOFA+ACAG</bold>
</td><td align="left" rowspan="1" colspan="1">0.700</td><td align="left" rowspan="1" colspan="1">0.680 - 0.721</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.333</td><td align="left" rowspan="1" colspan="1">0.901</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MELD+ACAG</bold>
</td><td align="left" rowspan="1" colspan="1">0.711</td><td align="left" rowspan="1" colspan="1">0.691 - 0.731</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.338</td><td align="left" rowspan="1" colspan="1">0.897</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>ROC, receiver operating characteristic; AUC, area under the curve; CI, confidence interval; AG, Anion Gap; ACAG, Albumin Corrected Anion Gap; MELD, Model for End-Stage Liver Disease; SOFA, Sepsis-related Organ Failure Assessment score.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="pone.0332490.g003" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0332490.g003</object-id><label>Fig 3</label><caption><title>ROC curves for predicting all-cause mortality in patients with cirrhosis at 30-d (A), 90-d (B),180-d (C) and 365-d (D) of hospital admission.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0332490.g003.jpg"/></fig><p>The decision curve analysis (DCA) for SOFA versus SOFA+ACAG and MELD versus MELD+ACAG across four follow-up periods (30-day, 90-day, 180-day, and 365-day) is presented in <bold>Supplementary Figures 1</bold> and 2 (<xref rid="pone.0332490.s004" ref-type="supplementary-material">S1 Fig</xref> and <xref rid="pone.0332490.s005" ref-type="supplementary-material">S2 Fig</xref>). At all time points, the curves for SOFA+ACAG and MELD+ACAG showed superior net benefit compared to SOFA and MELD alone, respectively. This indicates that incorporating ACAG into the MELD and SOFA scoring systems enhances mortality risk stratification and clinical utility.</p></sec><sec id="sec015"><title>3.4. Restricted Cubic Spline Analysis of ACAG in Relation to Cirrhosis Prognosis</title><p>In our study, we applied RCS analysis to identify the nonlinear relationships between ACAG and the prognosis of cirrhosis at different time points. The results at specific time points are as follows: 30 days (P&#8201;&lt;&#8201;0.001, P-Nonlinear&#8201;=&#8201;0.622), 90 days (P&#8201;&lt;&#8201;0.001, P-Nonlinear&#8201;=&#8201;0.429), 180 days (P&#8201;&lt;&#8201;0.001, P-Nonlinear&#8201;=&#8201;0.434), and 365 days (P&#8201;&lt;&#8201;0.001, P-Nonlinear&#8201;=&#8201;0.416). These findings suggest that an increase in ACAG is associated with a linear increase in mortality rates across all evaluated time points. For more detailed results, please refer to <bold><xref rid="pone.0332490.g004" ref-type="fig">Fig 4</xref></bold>.</p><fig position="float" id="pone.0332490.g004" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0332490.g004</object-id><label>Fig 4</label><caption><title>Association between ACAG and Survival with the RCS function at 30-d (A), 90-d (B), 180-d (C) and 365-d (D) after admission.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0332490.g004.jpg"/></fig></sec><sec id="sec016"><title>3.5. Subgroup analyses of ACAG in Cirrhosis patients</title><p>In our subgroup analyses, we evaluated the influence of various factors, including age, sex, race, sepsis, AKI, variceal bleeding, SBP, HE, HRS and CRRT, on the outcomes. We observed no significant interaction between these factors and ACAG, indicating the robustness of the association between ACAG and cirrhosis prognosis (all interaction P-values &gt;0.005). These detailed findings are presented in <bold><xref rid="pone.0332490.g005" ref-type="fig">Fig 5</xref></bold>.</p><fig position="float" id="pone.0332490.g005" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0332490.g005</object-id><label>Fig 5</label><caption><title>Forest plots of subgroup analysis of the relationship between all-cause mortality and ACAG in patients with cirrhosis at admission 30-d (A), 90-d (B), 180-d (C), and 365-d (D).</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0332490.g005.jpg"/></fig></sec></sec><sec sec-type="conclusions" id="sec017"><title>4. Discussion</title><p>Liver cirrhosis is associated with a poor prognosis, marked by high rates of morbidity and mortality [<xref rid="pone.0332490.ref024" ref-type="bibr">24</xref>]. In the ICU setting, patients with liver cirrhosis face an even more dismal outlook due to the severity of their condition and the frequent coexistence of multiple comorbidities [<xref rid="pone.0332490.ref025" ref-type="bibr">25</xref>]. Accurate prognosis assessment is thus critical for informing clinical decisions and enhancing patient outcomes. Currently, ICUs utilize multiple prognostic scoring systems, such as the SOFA score and the MELD score, to evaluate disease severity. However, these systems are often complex and time-consuming to calculate, limiting their rapid deployment in clinical practice. While recent research has focused on developing simpler indicators like the international normalized ratio-to-albumin ratio [<xref rid="pone.0332490.ref026" ref-type="bibr">26</xref>], lactate-to-albumin ratio [<xref rid="pone.0332490.ref027" ref-type="bibr">27</xref>], and neutrophil-to-lymphocyte ratio [<xref rid="pone.0332490.ref028" ref-type="bibr">28</xref>] to facilitate rapid prognosis assessment in patients with liver cirrhosis, there remains a critical need for even more straightforward and accessible indicators to guide clinicians in the timely management of critically ill patients.</p><p>In this study, univariate and multivariate analyses were performed on critically ill patients with liver cirrhosis, revealing that the ACAG serves as an independent predictor of both short-term and long-term all-cause mortality in severe liver cirrhosis. Patients were stratified into two groups based on ACAG levels: normal AG and high AG. K-M survival analysis demonstrated significantly worse short-term and long-term prognoses in the high ACAG group. ACAG levels exhibited moderate discriminative ability in predicting mortality at multiple time points in cirrhotic patients. However, the current evidence suggests that ACAG may serve as a potential supplementary tool rather than outperform well-validated scoring systems such as SOFA or MELD. Additionally, RCS analysis identified a linear relationship between ACAG levels and cirrhosis prognosis, indicating that elevated ACAG is associated with poorer outcomes. Subgroup analysis further confirmed the absence of significant interactions between ACAG and other prognostic factors in severe liver cirrhosis, underscoring the reliability of ACAG as a robust prognostic marker.</p><p>Multiple studies have established a robust correlation between the ACAG and disease prognosis across various conditions. For instance, a study involving 344 patients with acute pancreatitis by Li et al [<xref rid="pone.0332490.ref029" ref-type="bibr">29</xref>]. revealed that individuals with ACAG levels exceeding 19 exhibited a significantly higher in-hospital mortality rate (HR: 3.46), underscoring the independent association between elevated ACAG and increased mortality risk in this population. Similarly, a retrospective analysis of 1,561 asthma patients by Wang et al. identified elevated ACAG as an independent predictor of 30-day outcomes in critically ill asthma patients (HR: 1.07), with ACAG demonstrating superior predictive accuracy compared to the traditional anion gap [<xref rid="pone.0332490.ref022" ref-type="bibr">22</xref>]. Additionally, a retrospective study [<xref rid="pone.0332490.ref030" ref-type="bibr">30</xref>] found that elevated ACAG was a significant risk factor for 30-day all-cause mortality in critically ill patients with acute myocardial infarction (HR: 1.75). Comparable associations have been reported in other conditions, including sepsis [<xref rid="pone.0332490.ref031" ref-type="bibr">31</xref>], cardiogenic shock [<xref rid="pone.0332490.ref023" ref-type="bibr">23</xref>], and acute kidney injury [<xref rid="pone.0332490.ref032" ref-type="bibr">32</xref>]. Collectively, these findings affirm ACAG as a reliable biochemical marker and provide a robust clinical foundation for our research.</p><p>The AG is a fundamental parameter for evaluating acid-base disturbances, particularly in diagnosing metabolic acidosis in cirrhosis [<xref rid="pone.0332490.ref033" ref-type="bibr">33</xref>]. Progressive hepatic dysfunction in these patients leads to metabolic derangements, including: (1) impaired lactate metabolism&#8212;causing systemic accumulation, Type A lactic acidosis (secondary to tissue hypoxia and hemodynamic instability) [<xref rid="pone.0332490.ref034" ref-type="bibr">34</xref>,<xref rid="pone.0332490.ref035" ref-type="bibr">35</xref>], and Type B lactic acidosis (due to reduced hepatic perfusion and clearance) [<xref rid="pone.0332490.ref036" ref-type="bibr">36</xref>,<xref rid="pone.0332490.ref037" ref-type="bibr">37</xref>], often manifesting as mixed lactic acidosis with elevated AG; (2) impaired ketone regulation, which may precipitate ketoacidosis, especially in diabetics or insulin-deficient individuals [<xref rid="pone.0332490.ref038" ref-type="bibr">38</xref>,<xref rid="pone.0332490.ref039" ref-type="bibr">39</xref>]]; and (3) renal insufficiency, a common complication in advanced cirrhosis that exacerbates acidosis [<xref rid="pone.0332490.ref040" ref-type="bibr">40</xref>]. These mechanisms underscore the importance of AG monitoring for early detection and intervention [<xref rid="pone.0332490.ref041" ref-type="bibr">41</xref>]. Additionally, hypoalbuminemia&#8212;a hallmark of cirrhosis&#8212;significantly impacts AG as albumin is a major unmeasured anion [<xref rid="pone.0332490.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0332490.ref042" ref-type="bibr">42</xref>]. Conventional AG may underestimate acid-base disturbances in these patients, necessitating albumin-corrected AG (ACAG) for accurate assessment [<xref rid="pone.0332490.ref043" ref-type="bibr">43</xref>].</p><p>The SOFA score, despite its widespread use in intensive care, has limited relevance to cirrhotic patients due to their unique pathophysiology [<xref rid="pone.0332490.ref044" ref-type="bibr">44</xref>]. Similarly, the MELD score, though it is the current standard for prognosis, only considers a few biochemical parameters (INR, creatinine, and bilirubin), so it cannot account for critical complications like hepatic encephalopathy, spontaneous bacterial peritonitis, and variceal hemorrhage [<xref rid="pone.0332490.ref045" ref-type="bibr">45</xref>,<xref rid="pone.0332490.ref046" ref-type="bibr">46</xref>]]. Recent modifications, such as incorporating serum sodium (MELD-Na) or additional variables like age and albumin (MELD 3.0), have shown improved prognostic performance, underscoring the need for score optimization [<xref rid="pone.0332490.ref047" ref-type="bibr">47</xref>,<xref rid="pone.0332490.ref048" ref-type="bibr">48</xref>].</p><p>The ACAG introduced in this study can mitigate these limitations to some extent. As a robust indicator of acid-base disturbances, ACAG elevation correlates strongly with metabolic acidosis severity, hepatic impairment, and adverse clinical outcomes. By incorporating albumin alongside anion gap measurements, ACAG provides a more comprehensive representation of patient pathophysiology. Importantly, our data show that ACAG enhances mortality risk prediction when combined with either MELD or SOFA scores, offering a valuable advancement in cirrhosis prognostic modeling.</p><p>Clinically, ACAG offers several distinct advantages. It enables rapid risk stratification of critically ill cirrhotic patients, facilitating timely clinical decision-making. Elevated values predict adverse outcomes and warrant aggressive intervention, while lower values may support therapeutic de-escalation. This risk stratification promotes resource optimization and personalized treatment. The practical implementation of ACAG is further enhanced by its reliance on routinely available laboratory measurements (albumin and anion gap), eliminating the need for additional testing while maintaining cost &#8211; effectiveness and clinical accessibility.</p><p>Our research is constrained by several notable limitations. Firstly, the investigation was conducted within a single-center framework. Although we integrated an extensive sample of real-world data, the applicability of our findings may be limited across varied geographic regions and heterogeneous populations. Secondly, the study did not evaluate the severity grading or the underlying etiology of the disease, factors which could potentially narrow the scope of our results&#8217; interpretability. Moreover, we were unable to determine the definitive causes of mortality for all patients, as death in critically ill individuals is frequently attributable to a confluence of multiple factors. Lastly, the study population exclusively comprised patients admitted to the ICU, a characteristic that may introduce selection bias and limit the generalizability of our conclusions.</p></sec><sec sec-type="conclusions" id="sec018"><title>5. Conclusion</title><p>This study demonstrates that ACAG levels in cirrhotic patients are significantly associated with both short- and long-term clinical outcomes. Further validation through large-scale, multicenter prospective cohort studies is warranted to confirm these findings and evaluate the broader applicability of ACAG across heterogeneous patient populations.</p></sec><sec id="sec019" sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pone.0332490.s001" position="float" content-type="local-data" orientation="portrait"><label>S1 Table</label><caption><p>Results of the sensitivity analysis.</p><p>(DOCX)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0332490.s001.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0332490.s002" position="float" content-type="local-data" orientation="portrait"><label>S1 File</label><caption><title>R code used for statistical analyses.</title><p>(RAR)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0332490.s002.rar" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0332490.s003" position="float" content-type="local-data" orientation="portrait"><label>S2 File</label><caption><title>Database.</title><p>Source database used for the analyses in this study.</p><p>(CSV)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0332490.s003.csv" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0332490.s004" position="float" content-type="local-data" orientation="portrait"><label>S1 Fig</label><caption><p>DCA curves for SOFA versus SOFA+ACAG in patients with cirrhosis at 30-d (A), 90-d (B), 180-d (C), and 365-d (D) of hospital admission.</p><p>(TIF)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0332490.s004.tif" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0332490.s005" position="float" content-type="local-data" orientation="portrait"><label>S2 Fig</label><caption><title>DCA curves for MELD versus MELD+ACAG in patients with cirrhosis at 30-d (A), 90-d (B), 180-d (C), and 365-d (D) of hospital admission.</title><p>(TIF)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0332490.s005.tif" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0332490.ref001"><label>1</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Roehlen</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Crouchet</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Baumert</surname><given-names>TF</given-names></name>. <article-title>Liver fibrosis: mechanistic concepts and therapeutic perspectives</article-title>. <source>Cells</source>. <year>2020</year>;<volume>9</volume>(<issue>4</issue>):<fpage>875</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/cells9040875</pub-id><pub-id pub-id-type="pmid">32260126</pub-id><pub-id pub-id-type="pmcid">PMC7226751</pub-id></mixed-citation></ref><ref id="pone.0332490.ref002"><label>2</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chaudhuri</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Sasaki</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Karkar</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sharif</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lewis</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Mammen</surname><given-names>MJ</given-names></name>, <etal>et al</etal>. <article-title>Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis</article-title>. <source>Intensive Care Med</source>. <year>2021</year>;<volume>47</volume>(<issue>5</issue>):<fpage>521</fpage>&#8211;<lpage>37</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00134-021-06394-2</pub-id><pub-id pub-id-type="pmid">33876268</pub-id><pub-id pub-id-type="pmcid">PMC8054852</pub-id></mixed-citation></ref><ref id="pone.0332490.ref003"><label>3</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Arroyo</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Angeli</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Moreau</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Jalan</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Cl&#224;ria</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Trebicka</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis</article-title>. <source>J Hepatol</source>. <year>2021</year>;<volume>74</volume>(<issue>3</issue>):<fpage>670</fpage>&#8211;<lpage>85</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jhep.2020.11.048</pub-id><pub-id pub-id-type="pmid">33301825</pub-id></mixed-citation></ref><ref id="pone.0332490.ref004"><label>4</label><mixed-citation publication-type="journal"><name name-style="western"><surname>D&#8217;Amico</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Pasta</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Morabito</surname><given-names>A</given-names></name>, <name name-style="western"><surname>D&#8217;Amico</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Caltagirone</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Malizia</surname><given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2014</year>;<volume>39</volume>(<issue>10</issue>):<fpage>1180</fpage>&#8211;<lpage>93</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/apt.12721</pub-id><pub-id pub-id-type="pmid">24654740</pub-id></mixed-citation></ref><ref id="pone.0332490.ref005"><label>5</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Younossi</surname><given-names>ZM</given-names></name>, <name name-style="western"><surname>Stepanova</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Younossi</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Golabi</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Mishra</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Rafiq</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Epidemiology of chronic liver diseases in the USA in the past three decades</article-title>. <source>Gut</source>. <year>2020</year>;<volume>69</volume>(<issue>3</issue>):<fpage>564</fpage>&#8211;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/gutjnl-2019-318813</pub-id><pub-id pub-id-type="pmid">31366455</pub-id></mixed-citation></ref><ref id="pone.0332490.ref006"><label>6</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Achanti</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Szerlip</surname><given-names>HM</given-names></name>. <article-title>Acid-Base Disorders in the Critically Ill Patient</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>2023</year>;<volume>18</volume>(<issue>1</issue>):<fpage>102</fpage>&#8211;<lpage>12</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2215/CJN.04500422</pub-id><pub-id pub-id-type="pmid">35998977</pub-id><pub-id pub-id-type="pmcid">PMC10101555</pub-id></mixed-citation></ref><ref id="pone.0332490.ref007"><label>7</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ayala-Lopez</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Harb</surname><given-names>R</given-names></name>. <article-title>Interpreting Anion Gap Values in Adult and Pediatric Patients: Examining the Reference Interval</article-title>. <source>J Appl Lab Med</source>. <year>2020</year>;<volume>5</volume>(<issue>1</issue>):<fpage>126</fpage>&#8211;<lpage>35</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1373/jalm.2019.029496</pub-id><pub-id pub-id-type="pmid">32445342</pub-id></mixed-citation></ref><ref id="pone.0332490.ref008"><label>8</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jim&#233;nez</surname><given-names>JV</given-names></name>, <name name-style="western"><surname>Carrillo-P&#233;rez</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Rosado-Canto</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Garc&#237;a-Ju&#225;rez</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Torre</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kershenobich</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Electrolyte and Acid-Base Disturbances in End-Stage Liver Disease: A Physiopathological Approach</article-title>. <source>Dig Dis Sci</source>. <year>2017</year>;<volume>62</volume>(<issue>8</issue>):<fpage>1855</fpage>&#8211;<lpage>71</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s10620-017-4597-8</pub-id><pub-id pub-id-type="pmid">28501971</pub-id></mixed-citation></ref><ref id="pone.0332490.ref009"><label>9</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Scheiner</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Lindner</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Reiberger</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Schneeweiss</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Trauner</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zauner</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Acid-base disorders in liver disease</article-title>. <source>J Hepatol</source>. <year>2017</year>;<volume>67</volume>(<issue>5</issue>):<fpage>1062</fpage>&#8211;<lpage>73</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jhep.2017.06.023</pub-id><pub-id pub-id-type="pmid">28684104</pub-id></mixed-citation></ref><ref id="pone.0332490.ref010"><label>10</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gao</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>M-T</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>X-Y</given-names></name>, <name name-style="western"><surname>Cai</surname><given-names>M-X</given-names></name>, <name name-style="western"><surname>Nan</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>W</given-names></name>, <etal>et al</etal>. <article-title>Metabolic acidosis in critically ill patients with cirrhosis: Epidemiology and short-term mortality risk factors</article-title>. <source>Turk J Gastroenterol</source>. <year>2019</year>;<volume>30</volume>(<issue>10</issue>):<fpage>883</fpage>&#8211;<lpage>91</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.5152/tjg.2019.18813</pub-id><pub-id pub-id-type="pmid">31633484</pub-id><pub-id pub-id-type="pmcid">PMC6812953</pub-id></mixed-citation></ref><ref id="pone.0332490.ref011"><label>11</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rossiter</surname><given-names>N</given-names></name>. <article-title>Levelling up: prioritisation of global health</article-title>. <source>Eur J Orthop Surg Traumatol</source>. <year>2023</year>;<volume>33</volume>(<issue>3</issue>):<fpage>559</fpage>&#8211;<lpage>63</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00590-022-03394-w</pub-id><pub-id pub-id-type="pmid">36173480</pub-id><pub-id pub-id-type="pmcid">PMC9521009</pub-id></mixed-citation></ref><ref id="pone.0332490.ref012"><label>12</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Figge</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Jabor</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kazda</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Fencl</surname><given-names>V</given-names></name>. <article-title>Anion gap and hypoalbuminemia</article-title>. <source>Crit Care Med</source>. <year>1998</year>;<volume>26</volume>(<issue>11</issue>):<fpage>1807</fpage>&#8211;<lpage>10</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/00003246-199811000-00019</pub-id><pub-id pub-id-type="pmid">9824071</pub-id></mixed-citation></ref><ref id="pone.0332490.ref013"><label>13</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ayd&#305;n</surname><given-names>S&#350;</given-names></name>, <name name-style="western"><surname>Aksakal</surname><given-names>E</given-names></name>. <article-title>Relationship Between Albumin-Corrected Anion Gap and Mortality in Hospitalized Heart Failure Patients</article-title>. <source>Cureus</source>. <year>2023</year>;<volume>15</volume>(<issue>9</issue>):e45967. <comment>doi: </comment><pub-id pub-id-type="doi">10.7759/cureus.45967</pub-id><pub-id pub-id-type="pmid">37900402</pub-id><pub-id pub-id-type="pmcid">PMC10600590</pub-id></mixed-citation></ref><ref id="pone.0332490.ref014"><label>14</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Lan</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>X</given-names></name>. <article-title>Association between albumin-corrected anion gap and kidney function in individuals with hypertension - NHANES 2009-2016 cycle</article-title>. <source>Ren Fail</source>. <year>2024</year>;<volume>46</volume>(<issue>2</issue>):<fpage>2416719</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/0886022X.2024.2416719</pub-id><pub-id pub-id-type="pmid">39466713</pub-id><pub-id pub-id-type="pmcid">PMC11520097</pub-id></mixed-citation></ref><ref id="pone.0332490.ref015"><label>15</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hu</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name>. <article-title>Albumin corrected anion gap for predicting in-hospital mortality among intensive care patients with sepsis: A retrospective propensity score matching analysis</article-title>. <source>Clin Chim Acta</source>. <year>2021</year>;<volume>521</volume>:<fpage>272</fpage>&#8211;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cca.2021.07.021</pub-id><pub-id pub-id-type="pmid">34303712</pub-id></mixed-citation></ref><ref id="pone.0332490.ref016"><label>16</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Johnson</surname><given-names>AEW</given-names></name>, <name name-style="western"><surname>Bulgarelli</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Gayles</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Shammout</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Horng</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>MIMIC-IV, a freely accessible electronic health record dataset</article-title>. <source>Sci Data</source>. <year>2023</year>;<volume>10</volume>(<issue>1</issue>):<fpage>1</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41597-022-01899-x</pub-id><pub-id pub-id-type="pmid">36596836</pub-id><pub-id pub-id-type="pmcid">PMC9810617</pub-id></mixed-citation></ref><ref id="pone.0332490.ref017"><label>17</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kamath</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>Wiesner</surname><given-names>RH</given-names></name>, <name name-style="western"><surname>Malinchoc</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kremers</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Therneau</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Kosberg</surname><given-names>CL</given-names></name>, <etal>et al</etal>. <article-title>A model to predict survival in patients with end-stage liver disease</article-title>. <source>Hepatology</source>. <year>2001</year>;<volume>33</volume>(<issue>2</issue>):<fpage>464</fpage>&#8211;<lpage>70</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1053/jhep.2001.22172</pub-id><pub-id pub-id-type="pmid">11172350</pub-id></mixed-citation></ref><ref id="pone.0332490.ref018"><label>18</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Vincent</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Moreno</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Takala</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Willatts</surname><given-names>S</given-names></name>, <name name-style="western"><surname>De Mendon&#231;a</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bruining</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine</article-title>. <source>Intensive Care Med</source>. <year>1996</year>;<volume>22</volume>(<issue>7</issue>):<fpage>707</fpage>&#8211;<lpage>10</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/BF01709751</pub-id><pub-id pub-id-type="pmid">8844239</pub-id></mixed-citation></ref><ref id="pone.0332490.ref019"><label>19</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tang</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ishwaran</surname><given-names>H</given-names></name>. <article-title>Random Forest Missing Data Algorithms</article-title>. <source>Stat Anal Data Min</source>. <year>2017</year>;<volume>10</volume>(<issue>6</issue>):<fpage>363</fpage>&#8211;<lpage>77</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/sam.11348</pub-id><pub-id pub-id-type="pmid">29403567</pub-id><pub-id pub-id-type="pmcid">PMC5796790</pub-id></mixed-citation></ref><ref id="pone.0332490.ref020"><label>20</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Stekhoven</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>B&#252;hlmann</surname><given-names>P</given-names></name>. <article-title>MissForest--non-parametric missing value imputation for mixed-type data</article-title>. <source>Bioinformatics</source>. <year>2012</year>;<volume>28</volume>(<issue>1</issue>):<fpage>112</fpage>&#8211;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bioinformatics/btr597</pub-id><pub-id pub-id-type="pmid">22039212</pub-id></mixed-citation></ref><ref id="pone.0332490.ref021"><label>21</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sheng</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Dong</surname><given-names>H</given-names></name>. <article-title>The correlation between albumin-corrected anion gap and prognosis in patients with acute myocardial infarction</article-title>. <source>ESC Heart Fail</source>. <year>2024</year>;<volume>11</volume>(<issue>2</issue>):<fpage>826</fpage>&#8211;<lpage>36</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/ehf2.14639</pub-id><pub-id pub-id-type="pmid">38164072</pub-id><pub-id pub-id-type="pmcid">PMC10966208</pub-id></mixed-citation></ref><ref id="pone.0332490.ref022"><label>22</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Teng</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name>. <article-title>The relationship between albumin corrected anion gap levels and mortality in patients with asthma in the ICU</article-title>. <source>Sci Rep</source>. <year>2023</year>;<volume>13</volume>(<issue>1</issue>):<fpage>16903</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-023-44182-8</pub-id><pub-id pub-id-type="pmid">37803051</pub-id><pub-id pub-id-type="pmcid">PMC10558512</pub-id></mixed-citation></ref><ref id="pone.0332490.ref023"><label>23</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Tao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ying</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Relationship between the albumin-corrected anion gap and short-term prognosis among patients with cardiogenic shock: a retrospective analysis of the MIMIC-IV and eICU databases</article-title>. <source>BMJ Open</source>. <year>2024</year>;<volume>14</volume>(<issue>10</issue>):e081597. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/bmjopen-2023-081597</pub-id><pub-id pub-id-type="pmid">39357986</pub-id><pub-id pub-id-type="pmcid">PMC11448225</pub-id></mixed-citation></ref><ref id="pone.0332490.ref024"><label>24</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Engelmann</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Cl&#224;ria</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Szabo</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Bosch</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bernardi</surname><given-names>M</given-names></name>. <article-title>Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction</article-title>. <source>J Hepatol</source>. <year>2021</year>;75 Suppl 1(Suppl 1):S49&#8211;<lpage>66</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jhep.2021.01.002</pub-id><pub-id pub-id-type="pmid">34039492</pub-id><pub-id pub-id-type="pmcid">PMC9272511</pub-id></mixed-citation></ref><ref id="pone.0332490.ref025"><label>25</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Adams</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Franklin</surname><given-names>C</given-names></name>. <article-title>Prognosis of patients with cirrhosis and chronic liver disease admitted to the medical intensive care unit</article-title>. <source>Crit Care Med</source>. <year>1989</year>;<volume>17</volume>(<issue>8</issue>):<fpage>843</fpage>&#8211;<lpage>4</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/00003246-198908000-00030</pub-id><pub-id pub-id-type="pmid">2752784</pub-id></mixed-citation></ref><ref id="pone.0332490.ref026"><label>26</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gao</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Cai</surname><given-names>M-X</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>M-T</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L-Z</given-names></name>, <name name-style="western"><surname>Ruan</surname><given-names>Q-Z</given-names></name>, <etal>et al</etal>. <article-title>Prognostic value of international normalized ratio to albumin ratio among critically ill patients with cirrhosis</article-title>. <source>Eur J Gastroenterol Hepatol</source>. <year>2019</year>;<volume>31</volume>(<issue>7</issue>):<fpage>824</fpage>&#8211;<lpage>31</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/MEG.0000000000001339</pub-id><pub-id pub-id-type="pmid">30601338</pub-id></mixed-citation></ref><ref id="pone.0332490.ref027"><label>27</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ye</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Ren</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Association between lactate-to-albumin ratio and all-cause mortality in cirrhosis patients: Analysis of the MIMIC-IV database</article-title>. <source>Med Intensiva (Engl Ed)</source>. <year>2025</year>;:<fpage>502145</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.medine.2025.502145</pub-id><pub-id pub-id-type="pmid">39956736</pub-id></mixed-citation></ref><ref id="pone.0332490.ref028"><label>28</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Prithweeraj</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Neutrophil-to-Lymphocyte Ratio and Albumin: New Serum Biomarkers to Predict the Prognosis of Male Alcoholic Cirrhosis Patients</article-title>. <source>Biomed Res Int</source>. <year>2020</year>;<volume>2020</volume>:<fpage>7268459</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1155/2020/7268459</pub-id><pub-id pub-id-type="pmid">33415154</pub-id><pub-id pub-id-type="pmcid">PMC7769654</pub-id></mixed-citation></ref><ref id="pone.0332490.ref029"><label>29</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wan</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name>, <etal>et al</etal>. <article-title>Albumin Corrected Anion Gap and the Risk of in-Hospital Mortality in Patients with Acute Pancreatitis: A Retrospective Cohort Study</article-title>. <source>J Inflamm Res</source>. <year>2023</year>;<volume>16</volume>:<fpage>2415</fpage>&#8211;<lpage>22</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2147/JIR.S412860</pub-id><pub-id pub-id-type="pmid">37313307</pub-id><pub-id pub-id-type="pmcid">PMC10258038</pub-id></mixed-citation></ref><ref id="pone.0332490.ref030"><label>30</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jian</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Duan</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ge</surname><given-names>L</given-names></name>. <article-title>Association between albumin corrected anion gap and 30-day all-cause mortality of critically ill patients with acute myocardial infarction: a retrospective analysis based on the MIMIC-IV database</article-title>. <source>BMC Cardiovasc Disord</source>. <year>2023</year>;<volume>23</volume>(<issue>1</issue>):<fpage>211</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12872-023-03200-3</pub-id><pub-id pub-id-type="pmid">37118662</pub-id><pub-id pub-id-type="pmcid">PMC10148465</pub-id></mixed-citation></ref><ref id="pone.0332490.ref031"><label>31</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Miao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>N</given-names></name>. <article-title>Association between albumin corrected anion gap and mortality in septic older adults</article-title>. <source>Geriatr Nurs</source>. <year>2024</year>;<volume>60</volume>:<fpage>580</fpage>&#8211;<lpage>5</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.gerinurse.2024.10.022</pub-id><pub-id pub-id-type="pmid">39461109</pub-id></mixed-citation></ref><ref id="pone.0332490.ref032"><label>32</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Qiu</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Association between albumin-corrected anion gap level and the risk of acute kidney injury in intensive care unit</article-title>. <source>Int Urol Nephrol</source>. <year>2024</year>;<volume>56</volume>(<issue>3</issue>):<fpage>1117</fpage>&#8211;<lpage>27</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11255-023-03755-2</pub-id><pub-id pub-id-type="pmid">37642797</pub-id></mixed-citation></ref><ref id="pone.0332490.ref033"><label>33</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kou</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Du</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Nie</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>W</given-names></name>, <name name-style="western"><surname>He</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Serum Anion Gap at Admission Predicts All-Cause Mortality in Critically Ill Patients With Cirrhosis: A Retrospective Cohort Study</article-title>. <source>Clin Transl Gastroenterol</source>. <year>2024</year>;<volume>15</volume>(<issue>9</issue>):e1. <comment>doi: </comment><pub-id pub-id-type="doi">10.14309/ctg.0000000000000734</pub-id><pub-id pub-id-type="pmid">38920294</pub-id><pub-id pub-id-type="pmcid">PMC11421715</pub-id></mixed-citation></ref><ref id="pone.0332490.ref034"><label>34</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Musso</surname><given-names>CG</given-names></name>, <name name-style="western"><surname>Juarez</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Glassock</surname><given-names>RJ</given-names></name>. <article-title>Water, electrolyte, acid-base, and trace elements alterations in cirrhotic patients</article-title>. <source>Int Urol Nephrol</source>. <year>2018</year>;<volume>50</volume>(<issue>1</issue>):<fpage>81</fpage>&#8211;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11255-017-1614-y</pub-id><pub-id pub-id-type="pmid">28608260</pub-id></mixed-citation></ref><ref id="pone.0332490.ref035"><label>35</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Luft</surname><given-names>FC</given-names></name>. <article-title>Lactic acidosis update for critical care clinicians</article-title>. <source>J Am Soc Nephrol</source>. <year>2001</year>;12 Suppl 17:S15-9. <comment>doi: </comment><pub-id pub-id-type="doi">10.1681/asn.v12suppl_1s15</pub-id><pub-id pub-id-type="pmid">11251027</pub-id></mixed-citation></ref><ref id="pone.0332490.ref036"><label>36</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jeppesen</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Mortensen</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Bendtsen</surname><given-names>F</given-names></name>, <name name-style="western"><surname>M&#248;ller</surname><given-names>S</given-names></name>. <article-title>Lactate metabolism in chronic liver disease</article-title>. <source>Scand J Clin Lab Invest</source>. <year>2013</year>;<volume>73</volume>(<issue>4</issue>):<fpage>293</fpage>&#8211;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3109/00365513.2013.773591</pub-id><pub-id pub-id-type="pmid">23514017</pub-id></mixed-citation></ref><ref id="pone.0332490.ref037"><label>37</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Oster</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Perez</surname><given-names>GO</given-names></name>. <article-title>Acid-base disturbances in liver disease</article-title>. <source>J Hepatol</source>. <year>1986</year>;<volume>2</volume>(<issue>2</issue>):<fpage>299</fpage>&#8211;<lpage>306</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0168-8278(86)80089-7</pub-id><pub-id pub-id-type="pmid">3958478</pub-id></mixed-citation></ref><ref id="pone.0332490.ref038"><label>38</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Horn</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Tacke</surname><given-names>F</given-names></name>. <article-title>Metabolic reprogramming in liver fibrosis</article-title>. <source>Cell Metab</source>. <year>2024</year>;<volume>36</volume>(<issue>7</issue>):<fpage>1439</fpage>&#8211;<lpage>55</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cmet.2024.05.003</pub-id><pub-id pub-id-type="pmid">38823393</pub-id></mixed-citation></ref><ref id="pone.0332490.ref039"><label>39</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mansour</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Obeidat</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Darweesh</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mahfouz</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Kuwada</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Pyrsopoulos</surname><given-names>NT</given-names></name>. <article-title>The Impact of Cirrhosis on Outcomes of Patients Admitted With Diabetic Ketoacidosis: A Nationwide Study</article-title>. <source>Cureus</source>. <year>2022</year>;<volume>14</volume>(<issue>6</issue>):e25870. <comment>doi: </comment><pub-id pub-id-type="doi">10.7759/cureus.25870</pub-id><pub-id pub-id-type="pmid">35836436</pub-id><pub-id pub-id-type="pmcid">PMC9275525</pub-id></mixed-citation></ref><ref id="pone.0332490.ref040"><label>40</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Matchett</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Simonetto</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Kamath</surname><given-names>PS</given-names></name>. <article-title>Renal Insufficiency in Patients with Cirrhosis</article-title>. <source>Clin Liver Dis</source>. <year>2023</year>;<volume>27</volume>(<issue>1</issue>):<fpage>57</fpage>&#8211;<lpage>70</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cld.2022.08.010</pub-id><pub-id pub-id-type="pmid">36400467</pub-id></mixed-citation></ref><ref id="pone.0332490.ref041"><label>41</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Reddy</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Mooradian</surname><given-names>AD</given-names></name>. <article-title>Clinical utility of anion gap in deciphering acid-base disorders</article-title>. <source>Int J Clin Pract</source>. <year>2009</year>;<volume>63</volume>(<issue>10</issue>):<fpage>1516</fpage>&#8211;<lpage>25</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1742-1241.2009.02000.x</pub-id><pub-id pub-id-type="pmid">19769708</pub-id></mixed-citation></ref><ref id="pone.0332490.ref042"><label>42</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name>. <article-title>Research Progress and Treatment Status of Liver Cirrhosis with Hypoproteinemia</article-title>. <source>Evid Based Complement Alternat Med</source>. <year>2022</year>;<volume>2022</volume>:<fpage>2245491</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1155/2022/2245491</pub-id><pub-id pub-id-type="pmid">35251204</pub-id><pub-id pub-id-type="pmcid">PMC8893996</pub-id></mixed-citation></ref><ref id="pone.0332490.ref043"><label>43</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Vichot</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Rastegar</surname><given-names>A</given-names></name>. <article-title>Use of anion gap in the evaluation of a patient with metabolic acidosis</article-title>. <source>Am J Kidney Dis</source>. <year>2014</year>;<volume>64</volume>(<issue>4</issue>):<fpage>653</fpage>&#8211;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1053/j.ajkd.2014.05.022</pub-id><pub-id pub-id-type="pmid">25132207</pub-id></mixed-citation></ref><ref id="pone.0332490.ref044"><label>44</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Liu</surname><given-names>L-N</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>Y-F</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>H</given-names></name>. <article-title>Correlations of three scoring systems with the prognosis of patients with liver cirrhosis complicated with sepsis syndrome</article-title>. <source>World J Gastrointest Surg</source>. <year>2025</year>;<volume>17</volume>(<issue>3</issue>):<fpage>99570</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.4240/wjgs.v17.i3.99570</pub-id><pub-id pub-id-type="pmid">40162414</pub-id><pub-id pub-id-type="pmcid">PMC11948096</pub-id></mixed-citation></ref><ref id="pone.0332490.ref045"><label>45</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Huo</surname><given-names>T-I</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>H-C</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>J-C</given-names></name>, <name name-style="western"><surname>Hou</surname><given-names>M-C</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>F-Y</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>P-C</given-names></name>, <etal>et al</etal>. <article-title>Limitation of the model for end-stage liver disease for outcome prediction in patients with cirrhosis-related complications</article-title>. <source>Clin Transplant</source>. <year>2006</year>;<volume>20</volume>(<issue>2</issue>):<fpage>188</fpage>&#8211;<lpage>94</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1399-0012.2005.00463.x</pub-id><pub-id pub-id-type="pmid">16640525</pub-id></mixed-citation></ref><ref id="pone.0332490.ref046"><label>46</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lau</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ahmad</surname><given-names>J</given-names></name>. <article-title>Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine</article-title>. <source>Hepat Med</source>. <year>2013</year>;<volume>5</volume>:<fpage>1</fpage>&#8211;<lpage>10</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2147/HMER.S9049</pub-id><pub-id pub-id-type="pmid">24696621</pub-id><pub-id pub-id-type="pmcid">PMC3953735</pub-id></mixed-citation></ref><ref id="pone.0332490.ref047"><label>47</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Biggins</surname><given-names>SW</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>WR</given-names></name>, <name name-style="western"><surname>Terrault</surname><given-names>NA</given-names></name>, <name name-style="western"><surname>Saab</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Balan</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Schiano</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Evidence-based incorporation of serum sodium concentration into MELD</article-title>. <source>Gastroenterology</source>. <year>2006</year>;<volume>130</volume>(<issue>6</issue>):<fpage>1652</fpage>&#8211;<lpage>60</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1053/j.gastro.2006.02.010</pub-id><pub-id pub-id-type="pmid">16697729</pub-id></mixed-citation></ref><ref id="pone.0332490.ref048"><label>48</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lin</surname><given-names>H-Y</given-names></name>, <name name-style="western"><surname>Loi</surname><given-names>PL</given-names></name>, <name name-style="western"><surname>Ng</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Teo</surname><given-names>W-Q</given-names></name>, <name name-style="western"><surname>Chung</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>MELD3.0 is superior to MELDNa and MELD for prediction of mortality in patients with cirrhosis: An external validation in a multi-ethnic population</article-title>. <source>JGH Open</source>. <year>2024</year>;<volume>8</volume>(<issue>6</issue>):e13098. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/jgh3.13098</pub-id><pub-id pub-id-type="pmid">38832135</pub-id><pub-id pub-id-type="pmcid">PMC11144281</pub-id></mixed-citation></ref></ref-list></back><sub-article article-type="aggregated-review-documents" id="pone.0332490.r001" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0332490.r001</article-id><title-group><article-title>Decision Letter 0</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kandula</surname><given-names initials="M">Manasa</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#169; 2025 Manasa Kandula</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Manasa Kandula</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1371/journal.pone.0332490" id="rel-obj001" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>0</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">21 May 2025</named-content>
</p><p>PONE-D-25-10489Albumin-Corrected Anion Gap as a Predictive Marker for Mortality in Critically Ill Cirrhosis Patients: An Analysis Based on the MIMIC-IV DatabasePLOS ONE</p><p>Dear Dr.&#160;yang,</p><p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#8217;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p><p>==============================&lt;h3 data-end="973" data-start="931"&gt;<bold>Required Revisions for Acceptance:</bold> &lt;/h3&gt;</p><p><list list-type="order"><list-item><p><bold>Clarification of Cirrhosis Diagnosis (ICD Codes)</bold></p><p>Please explicitly list the ICD-9/10 codes used to define cirrhosis in the Methods section (currently not specified).</p></list-item><list-item><p><bold>Handling of Missing Data</bold></p><p>Expand on your current explanation of missing data. You mention Random Forest imputation for &#8804;20% missingness&#8212;please justify this choice and specify which variables were imputed.</p></list-item></list>
</p><p><list list-type="bullet"><list-item><p><bold>Normality and Data Presentation</bold></p><p>Clarify whether tests for normality (e.g., Shapiro-Wilk) were performed. If data were not normally distributed, justify the use of mean &#177; SD over median (IQR) for continuous variables.</p></list-item></list>
</p><p><list list-type="bullet"><list-item><p><bold>Multivariate Model Construction</bold></p><p>Clearly describe the variable selection process for Model 2. State whether stepwise selection, expert judgment, or univariate p-values were used. Also confirm whether multicollinearity (e.g., using VIF) was assessed.</p></list-item></list>
</p><p><list list-type="bullet"><list-item><p><bold>Code and Dataset Availability</bold></p><p>Upload all relevant R code (particularly for ROC analysis, multivariate models, RCS plots, and subgroup analysis) and a de-identified dataset (in CSV format) as supplementary material. These are needed for transparency and reproducibility.</p></list-item></list>
</p><p><list list-type="bullet"><list-item><p><bold>Subgroup Analysis: Interaction Testing</bold></p><p>Clarify whether formal tests for interaction were conducted (i.e., inclusion of interaction terms in Cox models). If not, please either perform and report p-values for interaction or state explicitly why these were not included.</p></list-item></list>
</p><p><list list-type="bullet"><list-item><p><bold>Discussion and Interpretation of AUC Values</bold></p><p>Temper the language in your conclusions. The ROC AUC for ACAG (0.66&#8211;0.67) is modest. Please clarify that ACAG may complement&#8212;but not outperform&#8212;established tools like SOFA or MELD.</p></list-item></list>
</p><p><list list-type="bullet"><list-item><p><bold>Revision of Discussion Section</bold></p><p>Improve contextualization of your findings with prior literature on cirrhosis-related prognostic tools. Streamline redundant pathophysiology and highlight clinical relevance of ACAG in resource-limited settings.</p></list-item></list>
</p><p><list list-type="bullet"><list-item><p><bold>Revision of Conclusions</bold></p><p>Please soften your conclusions to reflect limitations inherent in a retrospective single-center database analysis (e.g., causal inference, external generalizability).</p></list-item></list>
</p><p><list list-type="bullet"><list-item><p><bold>Validation of X-tile Cutoff</bold></p></list-item></list>
</p><p><list list-type="bullet"><list-item><p>You report an ACAG cutoff of &gt;20 derived via X-tile. Please discuss its clinical applicability and consider a sensitivity analysis (e.g., evaluating model performance across other potential thresholds).</p></list-item></list>
</p><p>&lt;h3 data-end="3431" data-start="3370"&gt;<bold>Recommended Revisions (Not Mandatory for Acceptance):</bold> &lt;/h3&gt;</p><p><list list-type="order"><list-item><p><bold>Comparative Prognostic Value</bold></p><p>Provide clearer insights into how ACAG might be used alongside MELD and SOFA. A decision curve analysis or net reclassification index could add depth.</p></list-item></list>
</p><p><list list-type="bullet"><list-item><p><bold>Discussion Clarity</bold></p><p>The discussion on acid-base physiology, lactic/ketoacidosis, and albumin&#8217;s role is scientifically accurate but overly repetitive. Condense and focus on clinical applicability.</p></list-item></list>
</p><p><list list-type="bullet"><list-item><p><bold>Minor Language Editing</bold></p><p>The manuscript would benefit from a thorough English language edit to address minor grammar, punctuation, and typographical issues.</p></list-item></list>
</p><p>==============================</p><p>Please submit your revised manuscript by Jul 05 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at&#160;<email>plosone@plos.org</email> . When you're ready to submit your revision, log on to <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>Please include the following items when submitting your revised manuscript:</p><p><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list>
</p><p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p><p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ext-link-type="uri">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link> . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link> .</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Manasa Kandula</p><p>Academic Editor</p><p>PLOS ONE</p><p>Journal requirements:&#160;1. When submitting your revision, we need you to address these additional requirements.&#160;Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link>&#160;2. We note that there is identifying data in the Supporting Information file &#8220;AGAG&#8221;. Due to the inclusion of these potentially identifying data, we have removed this file from your file inventory. Prior to sharing human research participant data, authors should consult with an ethics committee to ensure data are shared in accordance with participant consent and all applicable local laws.&#160;Data sharing should never compromise participant privacy. It is therefore not appropriate to publicly share personally identifiable data on human research participants. The following are examples of data that should not be shared:&#160;-Name, initials, physical address-Ages more specific than whole numbers-Internet protocol (IP) address-Specific dates (birth dates, death dates, examination dates, etc.)-Contact information such as phone number or email address-Location data-ID numbers that seem specific (long numbers, include initials, titled &#8220;Hospital ID&#8221;) rather than random (small numbers in numerical order)&#160;Data that are not directly identifying may also be inappropriate to share, as in combination they can become identifying. For example, data collected from a small group of participants, vulnerable populations, or private groups should not be shared if they involve indirect identifiers (such as sex, ethnicity, location, etc.) that may risk the identification of study participants.&#160;Additional guidance on preparing raw data for publication can be found in our Data Policy (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/data-availability#loc-human-research-participant-data-and-other-sensitive-data" ext-link-type="uri">https://journals.plos.org/plosone/s/data-availability#loc-human-research-participant-data-and-other-sensitive-data</ext-link>) and in the following article: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bmj.com/content/340/bmj.c181.long.&#xA0;Please" ext-link-type="uri">http://www.bmj.com/content/340/bmj.c181.long.&#160;Please</ext-link> remove or anonymize all personal information (&lt;specific identifying information in file to be removed&gt;), ensure that the data shared are in accordance with participant consent, and re-upload a fully anonymized data set. Please note that spreadsheet columns with personal information must be removed and not hidden as all hidden columns will appear in the published file.&#160;3. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://journals.plos.org/plosone/s/supporting-information" ext-link-type="uri">http://journals.plos.org/plosone/s/supporting-information</ext-link>.</p><p>[Note: HTML markup is below. Please do not edit.]</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p>
<bold>Comments to the Author</bold>
</p><p>1. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #2:&#160;Yes</p><p>Reviewer #3:&#160;Yes</p><p>**********</p><p>2. Has the statistical analysis been performed appropriately and rigorously? </p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #2:&#160;Yes</p><p>Reviewer #3:&#160;Yes</p><p>**********</p><p>3. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#8212;e.g. participant privacy or use of data from a third party&#8212;those must be specified.</p><p>Reviewer #1:&#160;No</p><p>Reviewer #2:&#160;Yes</p><p>Reviewer #3:&#160;Yes</p><p>**********</p><p>4. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p><p>Reviewer #1:&#160;Yes</p><p>Reviewer #2:&#160;Yes</p><p>Reviewer #3:&#160;Yes</p><p>**********</p><p>5. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p><p><bold>Reviewer #1:</bold> &#160;This study "Albumin-Corrected Anion Gap as a Predictive Marker for Mortality in Critically Ill Cirrhosis Patients" explores a key and clinically relevant topic, investigating Albumin-Corrected Anion Gap (ACAG) as a predictive marker for mortality in critically ill cirrhotic patients. While this study utilizes a robust dataset (MIMIC-IV), several critical areas must be addressed before the manuscript can be considered for publication.</p><p>1) The diagnosis was based on the relevant International Classification of Diseases (ICD) codes. Which ICD codes were used to determine the diagnosis of cirrhosis?</p><p>2) As a retrospective study, missing values are inevitable. Could you please elaborate on how these missing values were handled in the method section?</p><p>3) In large databases like MIMIC-IV, data are usually not normally distributed. What are the rationales for the authors presenting the data as mean and standard deviation? Did the authors check the normality of the data?</p><p>4) Please explain how the variables were selected for multivariate analysis.</p><p>5) Did the study account for the potential impact of medications, such as diuretics or corticosteroids, on ACAG levels in critically ill patients?</p><p>6) The authors stated that they developed ROC curves using five parameters&#8212;ACAG, AG, ALB, SOFA score, and MELD score&#8212;to evaluate their predictive ability. However, the ROC curves did not perform well. Could the authors explain why these parameters did not yield better predictive performance?</p><p>7) Please provide the data in CSV files and the R code for performing the Restricted Cubic Spline Analysis of ACAG concerning cirrhosis prognosis.</p><p>8) Line 255: The authors stated that 'In our subgroup analyses, we evaluated the influence of various factors, including age, sex, race, sepsis, AKI, variceal bleeding, SBP, HE, HRS, and CRRT, on the outcomes.' Did the authors adjust for any stratified variables? If so, please provide the data and the R code used for the subgroup analysis.</p><p>9) Please provide the dataset used in the analysis (in CSV or Excel format) along with the full R code used to generate all tables and figures. The authors can upload these as supplementary materials during the revision process, including both the final dataset and the R scripts.</p><p>10) Kindly revise the discussion section to highlight the current study's findings while placing them in the context of existing literature on related diseases i.e. cirrhosis. The updated discussion should provide a critical analysis of how the results compare to or differ from previous research, focusing on potential mechanisms and clinical implications and suggesting areas for future research.</p><p>11) Please revise the conclusions to present a more cautious interpretation of the study findings, considering the study design limitations and/or sample size.</p><p><bold>Reviewer #2:</bold> &#160;The study addresses a clinically relevant and timely question regarding the prognostic value of albumin-corrected anion gap (ACAG) in critically ill cirrhotic patients. Utilizing a large-scale dataset (MIMIC-IV) enhances the credibility and reproducibility of your findings. Overall, the study is methodologically sound, clearly presented, and ethically compliant.</p><p>However, several minor revisions are necessary to enhance the manuscript before publication:</p><p>1.Please perform careful proofreading to correct minor grammatical and typographical errors throughout the manuscript.</p><p>2.Clearly justify or discuss the validation and robustness of the cutoff value (ACAG&gt;20) derived by X-tile software. Consider conducting sensitivity analyses or further discuss its applicability.</p><p>3.Provide a more thorough comparative analysis of ACAG with established prognostic models (MELD, SOFA scores). Clearly articulate how ACAG adds clinical value or could practically complement existing prognostic tools.</p><p>4.Address the moderate ROC AUC values (~0.66) explicitly, discussing their implications for clinical decision-making and the utility of ACAG as a standalone predictor.</p><p><bold>Reviewer #3:&#160;</bold> Clarify Model Building Strategy:</p><p>Please describe the rationale and method for selecting variables in multivariate models (Model 2).</p><p>Were variables checked for multicollinearity (e.g., VIF)?</p><p>Interaction Terms in Subgroup Analysis:</p><p>While the subgroup analysis is comprehensive, please clarify whether formal interaction tests were performed. If not, please include interaction p-values or state why they were omitted.</p><p>Interpretation of AUC Values:</p><p>The ROC AUC for ACAG (0.66&#8211;0.67) is modest and slightly inferior to MELD/SOFA. Please temper the conclusion and discuss ACAG as a complement&#8212;not a replacement&#8212;for established scores.</p><p>Discussion Clarity:</p><p>The Discussion is well-referenced but includes redundant explanations (e.g., repeated pathophysiology of acid-base balance and hypoalbuminemia). Consider streamlining.</p><p>Add brief commentary on how ACAG could potentially be used in clinical triage or early risk stratification, particularly in settings with limited resources.</p><p>Limitations Section:</p><p>This is already strong. Consider explicitly stating that causality cannot be inferred due to the retrospective observational design.</p><p>**********</p><p>6. PLOS authors have the option to publish the peer review history of their article (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link> ). If published, this will include your full peer review and any attached files.</p><p>If you choose &#8220;no&#8221;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link> .</p><p>Reviewer #1:&#160;<bold>Yes:&#160;</bold> Mohan Giri</p><p>Reviewer #2:&#160;No</p><p>Reviewer #3:&#160;No</p><p>**********</p><p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool,&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link> . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at&#160;<email>figures@plos.org</email> . Please note that Supporting Information files do not need this step.</p></body></sub-article><sub-article article-type="author-comment" id="pone.0332490.r002"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0332490.r002</article-id><title-group><article-title>Author response to Decision Letter 1</article-title></title-group><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="editor-report" id="rel-obj002" xml:lang="en" journal-id="PLoS One" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="40938881"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">2 Jun 2025</named-content>
</p><p>All modifications have been made in the WORD versions of the Response to Reviewers, the Revised Manuscript with Track Changes, and the supplementary materials.</p><supplementary-material id="pone.0332490.s007" position="float" content-type="local-data" orientation="portrait"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">Response to Reviewers.docx</named-content></p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0332490.s007.docx" position="float" orientation="portrait"/></supplementary-material></body></sub-article><sub-article article-type="editor-report" id="pone.0332490.r003" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0332490.r003</article-id><title-group><article-title>Decision Letter 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Abdelaziz</surname><given-names initials="T">Tarek</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#169; 2025 Tarek Abdelaziz</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Tarek Abdelaziz</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="reviewed-article" id="rel-obj003" xml:lang="en" journal-id="PLoS One" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="40938881"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">2 Sep 2025</named-content>
</p><p>Albumin-Corrected Anion Gap as a Predictive Marker for Mortality in Critically Ill Cirrhosis Patients: An Analysis Based on the MIMIC-IV Database</p><p>PONE-D-25-10489R1</p><p>Dear Dr. yang,</p><p>We&#8217;re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p><p>Within one week, you&#8217;ll receive an e-mail detailing the required amendments. When these have been addressed, you&#8217;ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p><p>An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">Editorial Manager&#174;</ext-link> &#160;and clicking the &#8216;Update My Information' link at the top of the page. For questions related to billing, please contact <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://plos.my.site.com/s/" ext-link-type="uri">billing support</ext-link> .</p><p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they&#8217;ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.</p><p>Kind regards,</p><p>Tarek Samy Abdelaziz, MD,FRCP</p><p>Academic Editor</p><p>PLOS ONE</p><p>Additional Editor Comments (optional):</p><p>Reviewers' comments:</p></body></sub-article><sub-article article-type="editor-report" id="pone.0332490.r004" specific-use="acceptance-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0332490.r004</article-id><title-group><article-title>Acceptance letter</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Abdelaziz</surname><given-names initials="T">Tarek</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#169; 2025 Tarek Abdelaziz</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Tarek Abdelaziz</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1371/journal.pone.0332490" id="rel-obj004" related-article-type="reviewed-article"/></front-stub><body><p>PONE-D-25-10489R1</p><p>PLOS ONE</p><p>Dear Dr. Yang,</p><p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.</p><p>At this stage, our production department will prepare your paper for publication. This includes ensuring the following:</p><p>* All references, tables, and figures are properly cited</p><p>* All relevant supporting information is included in the manuscript submission,</p><p>* There are no issues that prevent the paper from being properly typeset</p><p>You will receive further&#160;instructions from the production team, including instructions on how to review your proof when it&#160;is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.</p><p>Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.</p><p>You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://explore.plos.org/phishing" ext-link-type="uri">https://explore.plos.org/phishing</ext-link>.</p><p>If we can help with anything else, please email us at customercare@plos.org.</p><p>Thank you for submitting your work to PLOS ONE and supporting open access.</p><p>Kind regards,</p><p>PLOS ONE Editorial Office Staff</p><p>on behalf of</p><p>Professor Tarek Samy Abdelaziz</p><p>Academic Editor</p><p>PLOS ONE</p></body></sub-article></article></pmc-articleset>